Home

Transforming Healthcare with Evidence

hayesinfo@hayesinc.com | 215-855-0615




We rely on Hayes to provide unbiased, evidence-based resources as an integral part of our technology assessment process.

Dr. Tony Melaragno
Chief Administrative Officer and Clinical VP of Research, Legacy Good Samaritan Hospital

Photodynamic Therapy for Nonmelanoma Skin Cancer

Tuesday, October 19th, 2010

Purpose of Technology

The objective of photodynamic therapy for nonmelanoma skin cancer (NMSC) is to selectively destroy cancer lesions without harming the surrounding tissue. The destruction of cells within the cancerous lesion is achieved by treating each lesion with a photosensitizing compound and subsequently exposing the lesion to an appropriate light source. Photodynamic therapy is intended as an alternative to conventional surgical excision, cryotherapy, or other therapies for NMSC.

Questions addressed in this report include:

  • Is PDT effective for NMSC lesions, and how does PDT compare with other treatments for NMSC lesions?
  • What adverse effects are associated with PDT?
  • Have definitive patient selection criteria been established for the use of PDT for NMSC lesions?

These questions provide a framework for review and synthesis of the best available evidence, which is presented in this report, along with the Hayes Ratings for the technology. This report also provides background information about the condition being treated, a description of the technology, and the context for development of the technology. Other key elements addressed in the report include the regulatory status; applicable Medicare and commercial payer coverage policies; relevant ICD-9 and ICD-10 diagnosis codes; cost and cost effectiveness; credentialing; hospital length of stay; need for large case management; and ongoing and future clinical trials of the technology.

Stay Connected!

To receive email newsletters, updates, and special offers from Hayes, enter your email and press Submit.
Email

Social Media

More